Peter Brent Sampson, Oakville (CA); Miklos Feher, New York, NY (US); and Heinz W. Pauls, Oakville (CA)
Assigned to UNIVERSITY HEALTH NETWORK, Toronto (CA)
Filed by UNIVERSITY HEALTH NETWORK, Toronto (CA)
Filed on Feb. 10, 2021, as Appl. No. 17/172,511.
Application 15/886,104 is a division of application No. 15/029,373, granted, now 9,884,855, issued on Feb. 6, 2018, previously published as PCT/CA2014/051001, filed on Oct. 17, 2014.
Application 17/172,511 is a continuation of application No. 16/675,609, filed on Nov. 6, 2019, granted, now 10,919,886.
Application 16/675,609 is a continuation of application No. 16/389,119, filed on Apr. 19, 2019, granted, now 10,472,353, issued on Nov. 12, 2019.
Application 16/389,119 is a continuation of application No. 15/886,104, filed on Feb. 1, 2018, granted, now 10,392,374, issued on Aug. 27, 2019.
Claims priority of provisional application 61/892,564, filed on Oct. 18, 2013.
Prior Publication US 2021/0269428 A1, Sep. 2, 2021
Int. Cl. C07D 413/14 (2006.01)
CPC C07D 413/14 (2013.01)
11 Claims
1. A method of treating a subject with cancer, comprising administering to the subject an effective amount of a maleate salt of compound (I) represented by the following structural formula:
wherein the molar ration between compound (I) and maleic acid 1:1,
wherein the cancer is selected from the group consisting of lung cancer, breast cancer and colon cancer.
